Table 2.
Characteristics after propensity score matching
| Characteristics | Aspirin group (n=986) | Combination group (n=986) | P value |
| Age (years), mean±SD | 68.10±10.88 | 67.94±10.76 | 0.739 |
| Sex (male) | 618 (62.68%) | 601 (60.95%) | 0.431 |
| eGFR (mL/min/1.73 m2), mean±SD | 74.37±32.05 | 75.04±30.73 | 0.630 |
| Baseline creatinine (μmol/L), median (IQR) | 87 (68-117) | 85.5 (68–112) | 0.962 |
| Uric acid (μmol/L), mean±SD | 345.53±117.87 | 355.56±119.75 | 0.066 |
| BUN (mmol/L), median (IQR) | 5.85 (4.58–7.60) | 5.62 (4.37–7.58) | 0.932 |
| Haematocrit (%), mean±SD | 38.74±5.71 | 39.15±5.68 | 0.095 |
| Complication | |||
| Hypertension | 788 (79.92%) | 834 (84.58%) | 0.007* |
| Diabetes | 355 (36.00%) | 368 (37.32%) | 0.544 |
| Angina | 202 (20.49%) | 15 (1.52%) | <0.001* |
| Myocardial infarction | 32 (3.25%) | 27 (2.74%) | 0.509 |
| Heart failure | 70 (7.10%) | 72 (7.30%) | 0.862 |
| Anaemia | 400 (40.57%) | 341 (34.58%) | 0.006* |
| CKD | 327 (33.16%) | 306 (31.03%) | 0.311 |
| Nephrotoxic drug | |||
| Contrast agents | 266 (26.98%) | 126 (13.78%) | <0.001* |
| Diuretic | 150 (15.21%) | 140 (14.20%) | 0.525 |
| ACEI | 306 (31.03%) | 71 (7.20%) | <0.001* |
| ARB | 128 (12.98%) | 132 (13.39%) | 0.790 |
| Calcium antagonists | 467 (47.36%) | 499 (50.61%) | 0.149 |
| β-blocker | 306 (31.03%) | 71 (7.20%) | <0.001* |
| Cephalosporin | 172 (17.44%) | 159 (16.13%) | 0.433 |
| Statins | 729 (73.94%) | 750 (76.06%) | 0.275 |
*p <0.05.
ACEI, ACE inhibitor; ARB, angiotensin receptor inhibitor; BUN, blood urea nitrogen; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.